Japanese CRO Croee To Establish NPO To Accelerate Patient Enrollment Process
This article was originally published in PharmAsia News
Executive Summary
Japanese contract research organization Croee plans to establish a non-profit organization to help enroll more clinical trial participants in Japan. As a third-party organization, the NPO will manage the database and protect individual privacy, promote public awareness of clinical trials and conduct follow-up activities such as providing information on new drugs after market launch. In Japan, medical facilities conducting clinical trials for pharmaceutical companies will ask site management organizations to start looking for patients to enroll in clinical studies. Croee hopes the new NPO will establish the patient database beforehand and will introduce candidates for certain trials to SMOs and hospitals. Croee has signed contracts with 50 SMOs and 500 hospitals. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.